Why ALUNBRIG (brigatinib)?
ALUNBRIG: an effective once-daily treatment option in anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (aNSCLC) post crizotinib
Exceeds 1 year median PFSa in ALK+ aNSCLC patients post crizotinib1
- Systematic ORRb in 56% (97.5% CI 45–67) of patients2
- Systemic mPFSc of 16.7 months (95% CI 11.6–21.4 months)2
- mOS of 34.1 months (95% CI 27.7-NR)2
Effective in the central nervous system (CNS)
- Intracranial mPFSc,d of 18.4 months (95% CI 12.6–23.9) in patients with any brain metastases at baseline2-5
- Intracranial mDORc of 16.6 months (95% CI 3.7-NR) in patients with measurable brain metastases at baseline2-5
A generally manageable tolerability profile
- The most commone treatment-emergent adverse events are diarrhoea, nausea, cough and increased blood creatine phosphokinase6 which can be managed by dose modification/interruption1
- Patients should be provided with a Patient Alert Card (PAC). In the first 7 days, they should be closely monitored for adverse reactions, particularly pulmonary adverse reactions, and the dose adjusted or discontinued if necessary1
- The convenience of a single tablet, once dailyf, that can be taken with or without food1
- Treatment should be commenced at the 90mg dose and if tolerated increased to 180mg after 7 days1
a IRC and Investigator assessed.
b Investigator assessed.
c IRC assessed.
d Intracranial PFS does not include systemic (non-cranial) disease progression events.
e Occurred in ≥10% of patients at a frequency of ≥30% at any grade.
f 180 mg once daily with a 7-day-lead-in at 90 mg once daily.
- ALUNBRIG Summary of Product Characteristics.
- Huber RM, et al. Poster presentation at ASCO Annual Meeting 2018, Poster 384.
- Camidge DR, et al. J Clin Oncol 2018;36:2693–701.
- Ahn M-J, et al. Oral presentation at IASLC 18th World Conference on Lung Cancer, 2017.
- Ou S-HI, et al. Oral presentation at ESMO 2017, poster 1345P.
- Kim DW, et al. J Clin Oncol 2017;35:2490–8.